0625/26SCR019-18/R12RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
1
Nina Balanchivadze, MD
SCRI at Virginia Oncology Associates I The US Oncology Netw
Media Outlet Date Article / Coverage
Black Doctor 5/31/26 ASCO 2026 Highlights: Why Mental Health Support Belongs
in Every Cancer Care Plan
Manojkumar Bupathi, MD, MS
SCRI at Rocky Mountain Cancer Centers I The US Oncology Network
Media Outlet Date Article / Coverage
Urology Times 5/30/26 Mark Fleming, MD, and Manojkumar Bupathi, MD, Discuss
the Most Anticipated GU Data at ASCO 2026
UroToday 5/29/26 ASCO 2026: Real-World Characteristics, HRR Mutation
Testing, Treatment Patterns, and Outcomes of Patients With
mCSPC in the US Community Oncology Setting
Cancer Network 6/11/26 ASCO 2026: Translating the Top Prostate Cancer Data Into
Clinical Action
Cancer Network 6/25/26 ASCO 2026: Practice-Guiding Updates in Bladder and
Kidney Cancer
John Burke, MD
SCRI at Rocky Mountain Cancer Centers | The US Oncology Network
Media Outlet Date Article / Coverage
AJMC 5/31/26 frontMIND: Results With Tafasitamab Improve PFS 25%
Over R-CHOP for High-Risk DLBCL
The ASCO Post 6/1/26 John M. Burke, MD, on Newly Diagnosed DLBCL:
frontMIND Trial
Blood Cancers Today 6/12/26 Moving Beyond R-CHOP-Only Regimens in Frontline DLBCL
Oncology Learning
Network
6/19/26 Adding Tafasitamab and Lenalidomide to R-CHOP Improves
Outcomes in High-Risk Diffuse Large B-Cell Lymphoma
Continued ➔
